257 results about "Dermatologic disorders" patented technology

Embodiments of the present invention provide a wearable phototherapy device, comprising a flexible substrate supporting a plurality of light-emitting elements configured to emit therapeutic light of one or more wavelengths. The substrate conforms to a treatment surface and may be integrated into a mask, wrap, patch, or garment insert. A conductive thin-film layer with an integrated metal-grid structure limits current to the light-emitting elements. The elements are arranged in one or more treatment zones, each independently addressable to provide wavelength and intensity control. A connector assembly enables selective attachment and detachment of the substrate to a power and control module. The device provides uniform, targeted illumination for dermatological, cosmetic, or therapeutic applications while maintaining ergonomic comfort.

Some embodiments are directed to a skin treatment system that contains a laser generating device. A hydrogel patch may include a region, at a first side of the hydrogel patch, to be in contact with a person's skin. The region may contain an adsorbing medium (e.g., carbon black or any other substance that would have a similar effect) that, when receiving a laser beam from the laser generating device, results in Extracorporeal Shock Wave Therapy (“ESWT”) being applied to the person's skin to treat a dermatologic condition such as an epidermal or dermal tissue structure irregularity, cellulite, a stretch mark, a scar, scar-tissue, a hypertrophic scar, an acne scar, etc.

The present invention relates to matrix-forming cross-linked carboxyalkyl chitosan, to compositions comprising same, to a process for the preparation thereof and to various uses thereof, in particular in therapeutic, rheumatology, ophthalmology, cosmetic medicine, plastic surgery, open surgery, dermatology, gynecology or cosmetic fields. In particular, the invention relates to a substrate comprising at least one carboxyalkyl chitosan having glucosamine units, N-acetylglucosamine units and glucosamine units substituted with a carboxyalkyl group, expressed in the number of moles of N-acetyl groups relative to the number of moles of total glucosamine units, the acetylation degree of the carboxyalkyl chitosan is 40%-80%, and the carboxyalkyl chitosan is crosslinked through covalent bonds between carboxyalkyl chitosan chains.

The invention discloses TCN1 (Trancobalamin 1, cobalamin 1) and application of an inhibitor of the TCN1 in preparation of products for diagnosing and treating diseases of an autoimmune system. According to the invention, expression in psoriasis tissues is up-regulated and promoter DNA methylation is down-regulated into genes to screen TCN1 genes, an over-expression TCN1 HaCaT cell line is constructed, and it is verified that the over-expression TCN1 HaCaT cell line participates in keratinocyte proliferation and IL-17 activation as an autoantigen, can be used as a diagnostic marker and a therapeutic target of autoimmune skin diseases such as psoriasis and the like, and has broad application prospects. And a new direction is provided for mechanism research and treatment of autoimmune skin diseases such as psoriasis.

The present invention relates to the technical field of veterinary medicinal products and specifically to a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble. The composition has considerable curative effects on fungal infections on the skin surfaces of animals, with low toxicity and minimal irritation.

The invention discloses a compound with tyrosinase inhibitory activity and application of the compound in preparation of whitening products, and belongs to the technical field of medicinal chemistry. The compound is 5-(4-hydroxyphenyl)-3-O-glucosyl valeric acid, and is a novel compound. The compound can significantly inhibit the activity of tyrosinase, has the ability of blocking tyrosinase from catalyzing tyrosine to be converted into melanin precursor substances, and directly inhibits the generation of melanin, thereby showing better application prospects and values in skin whitening or skin diseases.

A hair care formulation for improving the tensile strength of damage hair is provided, comprising: (a) a dermatogically acceptable vehicle; and (b) a tensile strength improving additive; wherein the tensile strength improving additive comprises: (b1) a (±)-α-tocopherol; and (b2) a carboxy functional organosiloxane compound of formula (I) wherein x is 0 to 25; wherein each R1 is independently selected from an alkylene radical containing 1 to 10 carbon atoms; wherein each R2 is independently selected from the group consisting of an alkyl group of 1 to 18 carbon atoms, an aryl group of 6 to 18 carbon atoms, an acyloxy group of 2 to 18 carbon atoms, and a hydrocarbonoxy-functional group of 1 to 18 carbon atoms.

Provided herein are compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or dermatologic skin conditions. The compositions include black willow bark extract, cat's claw extract, and dragon's blood extract. The compositions ameliorate skin conditions including acne, rosacea, blemish, dermatitis, eczema, or the like.

The application discloses a sealed and heat-insulated automatic liquid nitrogen gun for a dermatosis treatment robot, and relates to the technical field of medical devices, which solves the problems of the existing liquid nitrogen gun in simultaneously solving flow closed-loop control, vaporization rate active adjustment, liquid nitrogen loss and robot adaptation, and realizes closed-loop flow control by containing a micro electric ball valve in a liquid nitrogen injection flow adjusting unit, changing the valve opening area in real time according to the deviation between the liquid nitrogen injection flow and the target flow detected by a micro turbine flowmeter, forming a switchable air heat transfer layer between the liquid nitrogen gun shell and the storage cavity in a vacuum layer heat transfer adjusting unit, opening the electromagnetic valve when the liquid nitrogen injection works, and extracting low-temperature air by a micro vacuum pump and introducing normal-temperature air from the outside to provide heat for liquid nitrogen vaporization and pressure increase, closing the electromagnetic valve when the work is stopped, and continuing to extract air by the vacuum pump until the heat transfer layer reaches the set negative pressure and then stops rotating to form a vacuum layer to prevent heat exchange between the inside and the outside of the liquid nitrogen cavity and enter the liquid nitrogen storage state.

To provide a method for evaluating the therapeutic and / or prophylactic action of a skin disease caused by the obstruction and / or inflammation of a pilosebaceous gland system.SOLUTION: A method for evaluating a therapeutic and / or prophylactic action of a substance or agent on a skin disease, the method comprising: bringing the substance or agent into contact with sebocytes or progenitor cells thereof; and evaluating the sebocytes or progenitor cells thereof, wherein the skin disease is a skin disease caused by obstruction and / or inflammation of the pilosebaceous unit.SELECTED DRAWING: None

The invention relates to a high-speed atomic force microscope (AFM, 1) for measuring a relevant sample (S), such as a skin sample, the AFM having a sensor unit (SU, 10) comprising a light source (11) and a collimating lens (12), the collimating lens being mechanically displaced by a collimating lens actuator (12 '). An AFM cantilever having an AFM tip (14) is arranged relative to the photodetection beam (15) for providing a focus error signal (FES) indicative of mechanical engagement with the sample. The collimating lens (12) is arranged to be adjusted by a collimating lens actuator (12 ') along the beam path to compensate for at least thermal drift in the focus error signal (FES). According to the invention, the improved high-speed AFM can be obtained through the internal thermal drift compensation mechanism. The high-speed AFM of the embodiment of the invention can have a theoretical linear scanning speed which can reach 700000 um / s, which allows one-time imaging to be completed within about 3.4 seconds.

A solid material including a matrix, dispersed in which are microparticles of at least one antimicrobial agent for preventing, limiting and / or eliminating the contamination of the material and / or the contamination of a composition which is in contact with the material for at least a given time, and / or preventing, eliminating and / or slowing down the formation of biofilms on the surface of the material, wherein the antimicrobial agent is an oxide of at least one positively charged metal ion and the antimicrobial agent does not migrate out of the material. Also, the use of such material for manufacturing an article, to the process for manufacturing the article, and to the article obtained. In particular, the article is selected from stoppers, lids, seals, caps, covers, plugs and valves intended for sealing bottles, flasks, jars, cans, canisters, barrels, tanks, or various containers used for packaging and / or storing food products, dietetic products, cosmetic products, dermatological products or pharmaceutical products.

The invention relates to a compound which is effective in inhibiting the function of the TRPM4 ion channel and the use of such compound in treating or preventing a TRPM4-associated disorder in a subject such as neurodegenerative diseases like stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and neurodegenerative disease under inflammatory conditions, in particular multiple sclerosis, or genodermatosis, cardiac diseases, and immunemediated diseases. The invention also provides a pharmaceutical composition comprising the TRPM4 inhibitory compound.

The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.

Dermatological compositions comprising amphiphilic peptides, derivatives or salts thereof are provided. The compositions are particularly useful as dermal fillers and for inducing soft tissue repair and regeneration.

The invention discloses a respiration assisting device for the cardiovascular medicine department, and relates to the technical field of cardiovascular medicine department machinery, the respiration assisting device comprises a linear guide rail, the surface of the linear guide rail is fixedly connected with a pressing plate, the output end of the linear guide rail is fixedly connected with a supporting table, and the side face position of the supporting table is fixedly connected with a side edge table; a pillow is fixedly connected to the middle of the top of the supporting table. According to the respiration assisting device for the cardiovascular medicine department, the inclination angle of a downward pressing assembly is increased, so that a sealing assembly makes close contact with the mouth and the nose of a patient, the bottom of a temperature and humidity adjusting mechanism is externally connected with an oxygen tank, and the temperature and humidity of oxygen are adjusted through the temperature and humidity adjusting mechanism and then introduced into the sealing assembly; the sealing assembly is tightly attached to the face of the patient through the pressing force of the downward pressing assemblies on the two sides, and the problems that due to the fact that the respirator makes close contact with the skin of the patient through water, the patient is prone to suffering from skin diseases, and the respirator cannot be effectively limited are solved.

The invention relates to methods of treatment and / or prevention of an immune-mediated inflammatory skin disease in a subject, wherein the therapeutic effects persist for at least 24 weeks or more after the last administration of the composition. Also disclosed are kits and methods of treating and / or preventing an immune-mediated inflammatory skin disease using said composition.

The present invention relates to antiperspirant and deodorant compositions for correction of body odour, and more particularly relates to antiperspirant and deodorant compositions for human hygiene. The disclosed anti-perspirant and deodorant composition comprises isobutane, propane, butane, cyclopentasiloxane, caprylic / capric triglyceride, stearalkonium hectorite, propylene carbonate, c12-15 alkyl benzoate, parfum, silver lactate, lactic acid, aqua, zea mays starch, menthyl ethylamido oxalate, argania spinosa kernel oil. Furthermore, the active antimicrobial silver ingredient is dermatologically tested and is capable of diminishing odor-causing bacteria in addition to prevention of irritation and itching.

The invention discloses a bovine nodular skin disease virus fusion antigen as well as a product and application thereof, and belongs to the technical field of immunity. In order to solve the technical problems that the immune antigen of the bovine nodular skin disease virus is poor in safety, not easy to prepare and low in immunogenicity, the technical scheme is characterized in that the fusion antigen aiming at the bovine nodular skin disease virus is provided, and the fusion antigen comprises three antigen peptide fragments derived from bovine nodular skin disease virus LSDV060 protein and LSDV122 protein, and the three antigen peptide fragments are fused through head-to-tail splicing.

The present invention relates to a dermatological composition in an essentially liquid form, in particular in the form of a serum, comprising epigallocatechin gallate (EGCG) and ascorbic acid.

The invention provides a pharmaceutical composition for treating inflammatory skin diseases, and particularly relates to an O / W cream containing trifarotene. The pharmaceutical composition provided by the invention has proper viscosity and elasticity, and the trifarotene composition preferably contains diethylene glycol monoethyl ether. The pharmaceutical composition can be directly applied to skin.

The present invention relates to methods of reducing occurrence or severity of dermatologic adverse events (DAEs) in a subject treated with an anti-epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody and EGFR tyrosine kinase inhibitor, comprising (a) administering an antibiotic(s); (b) administering an antiseptic(s); and (c) administering a non-comedogenic moisturizer to the subject.

The formulation is an antibacterial and antifungal ointment which comprises of oil of Raphanus sativa seeds, white wax and white petroleum jelly. The ointment acts as a potent antibacterial and antifungal agent and is especially effective against dermatophytes. In clinical trials the ointment was found to be effective, well tolerated and free from irritative and allergic reactions.

Modulated light therapy devices for treatment of dermatological disorders of the scalp are provided. An exemplary device includes a flexible printed circuit board (FPCB) supporting at least one light emitting device having an emitter height. The FPCB includes multiple interconnected panels and bending regions defined in and between at least some of the interconnected panels as to allow the FPCB to be configured in a concave shape to cover at least a portion of a cranial vertex of the patient. At least one light-transmissive layer proximate to the FPCB is configured to transmit (e.g., incoherent) light emissions generated by at least one light emitting device. At least one standoff is configured to be arranged between the FPCB and the scalp of the patient, wherein the at least one standoff includes a standoff height that exceeds the emitter height.

This invention discloses a GABA-loaded hydrogel microneedle, its preparation method, and its application, belonging to the field of biomedical materials technology. This drug-loading system uses polypyrrole-grafted gelatin (PPy) as the loading medium. ‑ Using gelatin (GelMA), carboxymethyl chitosan, and methacrylate gelatin (GelMA) as a matrix, a three-dimensional network hydrogel (PPG@Gel) is formed through cross-linking with aldehyde-modified polyethylene glycol (PEG-CHO) and loaded with γ-aminobutyric acid (GABA). The preparation process includes GelMA modification, PPy-GelMA graft polymerization, PEG-CHO cross-linking agent synthesis, and mixing of each component with GABA to form a precursor hydrogel (PPG@Gel), which can ultimately be prepared as a microneedle patch (PPG@MN). This invention utilizes the excellent biocompatibility and permeability of hydrogels to achieve precise local delivery of GABA to lesions in inflammatory skin diseases. GABA can target and inhibit abnormal inflammatory responses, regulate epidermal cell function, and repair the skin barrier, while avoiding the adverse reactions and cost drawbacks of existing treatments. The hydrogel raw materials are readily available and highly safe, allowing for continuous drug delivery to improve patient compliance. It is suitable for the treatment of various inflammatory skin diseases such as psoriasis and eczema, and has significant clinical application value.

The invention provides a rucotinib phosphate nanostructure lipid carrier, a preparation method and application thereof, and a rucotinib phosphate composition, and belongs to the technical field of pharmaceutical preparations. According to the rucotinib phosphate nanostructure lipid carrier and the rucotinib phosphate composition provided by the invention, the solid lipid and the liquid lipid are compounded, and the anti-crystallization agent is introduced, so that the rucotinib phosphate is encapsulated in the nanostructure lipid carrier core formed by the solid lipid and the liquid lipid; the problem of unique crystallization caused by a pyrazole structure of rucotinib phosphate is solved, and the compound has the advantages of high encapsulation efficiency and good stability. According to the invention, the rucotinib phosphate nanostructure lipid carrier is uniformly dispersed in a dermatologically acceptable matrix to obtain a composition containing a therapeutically effective amount of rucotinib phosphate, and the composition shows significantly enhanced drug stability and skin retention ability, and reduces the risk of system exposure.

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.

The present invention relates to a topical composition comprising a 100 μg / mL ethanolic extract from the plant Aspalathus linearis together with a dermatologically acceptable carrier for use in a method of preventing or treating a hypopigmentary disorder of skin in a subject comprising applying the topical composition to the skin of the subject. The invention further relates to methods of preventing or treating a hypopigmentary disorder of skin in a subject comprising applying the topical composition to the skin of the subject.

The invention discloses a fibroblast preparation and a preparation method and application thereof, and belongs to the technical field of biomedical engineering, and the fibroblast preparation is prepared by mixing and compounding fibroblasts, a carrier and an active substance solution. The preparation method comprises the following steps: S1, cell pretreatment; s2, preparing a cross-linked collagen fiber hydrogel; s3, preparing an active substance solution; and S4, preparing the fibroblast preparation. By pretreating fibroblasts, activating the anti-inflammatory phenotype of the fibroblasts, promoting the fibroblasts to secrete collagen, loading the cells through collagenous fiber hydrogel and adding active substances, the skin lesion is repaired, meanwhile, type II immune excessive activation is inhibited, and the clinical disease performance of eczema mice is remarkably improved. The problems of limited skin disease treatment and skin lesion repair effects caused by low cell survival rate, poor carrier biocompatibility and poor active substance synergism in the prior art are solved, and the preparation method has the potential of preparing drugs for treating skin diseases.

This disclosure provides antibodies that specifically bind to human PAR-2, antigen-binding fragments thereof, and compositions comprising such antibodies or antigen-binding fragments thereof. [Solution] In certain embodiments, an antibody or antigen-binding fragment thereof that specifically binds to human PAR-2 ​​blocks the interaction between the PAR-2 ​​activating ligand and the extracellular domain of PAR-2, and / or blocks PAR-2 ​​activation by the PAR-2 ​​activating ligand. In further embodiments, the antibody or antigen-binding fragment can be used to treat diseases or conditions associated with increased PAR-2 ​​expression, and / or diseases or conditions that can be alleviated by antagonizing the activation of PAR-2 ​​by the PAR-2 ​​activating ligand (e.g., respiratory diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).